ESC 24: Hot Line & Late-breaking Science Video Collection
Published: 15 August 2024
-
Views:
2589
-
Likes:
7
-
Views:
2589
-
Likes:
7
-
Up Next -
20m 14sPart 3 | Session 2 RHEIA: TAVR vs SAVR in Women with Severe AS -
8m 47sPart 3 | Session 3 OCEANIC-AF: Asundexian Vs Apixaban in Atrial Fibrillation -
9m 29sPart 3 | Session 4 SWEDEGRAFT: No-touch Vein Graft in CABG -
17m 28sPart 3 | Session 5 FINEARTS-HF: Finerenone HFmEF & HFpEF
-
6m 8s -
5m 29sPart 4 | Session 2 MATTERHORN: M-TEER vs Surgery in Heart Failure -
5m 46sPart 4 | Session 3 MRAs in Heart Failure -
4m 24sPart 4 | Session 4 FINE-HEART: Finerenone in HF & CKD -
8m 18sPart 4 | Session 5 STEEER-AF: Stroke Prevention & Rhythm Control Therapy -
3m 52sPart 4 | Session 6 NOTION-3: FFR Guided PCI in TAVI -
6m 48sPart 4 | Session 7 EPIC-CAD: Edoxaban vs Dual Antiplatelet Therapy in AF & CAD -
8m 17sPart 4 | Session 8 SENIOR RITA: Invasive Vs Conservative Strategy for Older Patients with MI -
3m 51sPart 4 | Session 9 EARTH-STEMI: Complete Vs Culprit-Only Revascularization in Older Patients -
4m 17sPart 4 | Session 10 SCOFF: Fasting vs. Non-Fasting: Impact on Cardiac Catheterization Outcomes -
4m 17sPart 4 | Session 11 GUARD-AF: Atrial Fibrillation Screening to Reduce Stroke in Elderly Individuals -
2m 31s -
7m 9sPart 4 | Session 13 POPular PAUSE TAVI: Continuation or interruption of OAC During TAVI
-
4m 54sPart 5 | Session 1 3 Trials That Will Change My Practice With Dr Muthiah Vaduganathan -
13m 47sPart 5 | Session 2 3 Trials That Will Change My Practice With Dr Michelle Kittleson
-
6m 55sPart 6 | Session 1 New Guidelines for the Management of Atrial Fibrillation -
6m 13sPart 6 | Session 2 New Guidelines for the Management of Aortic Diseases
-
47m 31sPart 1 | Session 1 ESC Congress 2024 Hot Line Wrap Up Nicolas M Van Mieghem, Joost Daemen
-
27m 27sPart 1 | Session 2 ESC Congress 2024 Hot Line Preview Nicolas M Van Mieghem, Joost Daemen
-
17m 25sPart 2 | Session 1 ESC Day 1 Wrap Up: New Guidelines, HELIOS-B, ABYSS & STOP-or-NOT Mirvat Alasnag, Khaled Al-Shaibi
-
23m 2sPart 2 | Session 2 ESC Day 2 Wrap-Up: NOTION-3, RESHAPE-HF2, TRI.Fr & More Mirvat Alasnag, Khaled Al-Shaibi
-
12m 28sPart 2 | Session 3 Day 3 Wrap-Up with Dr Alasnag and Dr Al-Shaibi Mirvat Alasnag, Khaled Al-Shaibi
-
15m 45sPart 2 | Session 4 Day 4 Wrap-Up: OCCUPI, REC-CAGEFREE I, AEGIS-II & More Mirvat Alasnag, Khaled Al-Shaibi
Overview
What's hot at the ESC Congress 2024?
Stay ahead of the curve with our faculty-led coverage of the European Society of Cardiology Congress in London. From groundbreaking trials to expert insights, we've got you covered.
- Watch our View From the Thoraxcenter series for practice-focused reviews of the most anticipated trials from interventional experts, Prof Nicolas Van Mieghem and Dr Joost Daemen.
- For a deeper dive into key hot line clinical trial data and its applicability, host, Dr Harriette Van Spall meets with principal investigators in her Late-Breaker Discussion series.
- View a condensed summary of the crucial takeaways from each day in our Wrap-Up series led by Dr Mirvat Alasnag.
- Our short, bite-sized Expert Interviews with select faculty will focus on data, take-home messages for practice and the future of their field.
Get ready for a deep dive into the latest cardiology research. Our coverage of the ESC Congress is coming soon.
More from this programme
Part 1
View From the Thoraxcenter: What's Hot at ESC 24?
Part 2
Daily Wrap Ups with Dr Alasnag and Dr Al-Shaibi
Part 3
Hot-line Discussions with Dr Harriette Van Spall
Part 4
Expert Interviews
Part 5
Highlights
Part 6
Guidelines
About the episode
ESC Congress 2024 — The interruption of beta blocker treatment was not non-inferior to a strategy of βB continuation.
Host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) sits down with investigator, Prof Johanne Silvain
(Pitié-Salpêtrière University Hospital, Paris, FR) to discuss key results from the AβYSS trial (NCT03498066; Assistance Publique - Hôpitaux de Paris).
The ABYSS trial aims to assess the efficacy of interrupting beta blocker (βB) therapy after six months of follow-up in patients with uncomplicated myocardial infarction (MI). The study enrolled 3700 patients and followed them for one year. The primary outcome is the occurrence of major adverse cardiovascular events (MACE).
Results did not demonstrate non-inferiority, with a 21% event rate in patients with interrupted βB therapy as compared to 19% in patients in the βB continuation group. In terms of secondary outcomes, there was no improvement in quality of life, and no significant difference in rates of MACE and heart failure between both groups.
Recorded remotely from Paris and Hamilton, 2024.
Editors: Jordan Rance and Mirjam Boros.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David-Ben-Harosh.
Support: This is an independent interview produced by Radcliffe Cardiology.
Faculty Biographies
Harriette Van Spall
Associate Professor of Medicine, Director of E-Health and Virtual Care
Dr Harriette Van Spall is an Associate Professor of Medicine and cardiologist and serves as Director of E-Health at McMaster University, Canada. She completed her medical and postgraduate clinical training at the University of Toronto and earned a Master of Public Health degree at Harvard University, US. Dr Van Spall is a Canadian Institutes of Health Research-funded clinical trialist and researcher with a focus on heart failure, health services, and health disparities.
She has garnered more than $4 million in research funding, has won several research awards, and has published her work in high-impact medical journals. She is an invited speaker, media correspondent, and editorial board member active in peer review at several high-impact medications journals and grant funding agencies, including Canadian Institutes of Health Research and Heart and Stroke Foundation of Canada.
Dr Van Spall is an Editorial Board…
Johanne Silvain
Prof. Johanne Silvain is professor of medicine at the Pierre and Marie Curie University in Paris, France.
He is an interventional cardiologist, with experience in coronary angioplasty and OTC, and is Director of the Coronary Intensive Care Unit. He is licensed at the University of Medicine of Paris (UPMC) and is the author of over 100 publications in prestigious authoritative journals. The research interests of Dr. Silvain fall within the field of thrombosis (composition of thrombi) and antithrombotic drugs (anticoagulant and antiplatelet agents) and the related repercussions on haemorrhages and transfusions.
Comments